← ANALYST RATINGS · TIPRANKS
Savara (SVRA): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy0 Hold0 Sell
Ratings of 6 analysts in the last 3 months12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $11.33, the highest $16.00, the lowest $9.00. The average is +154.7% from the last price of $4.45.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $5.00 → $4.50−10.0% | Hold | +1.1% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.50 → $4.00−11.1% | Hold | −10.1% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.50 → $4.00−11.1% | Hold | −10.1% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| Unknown Analyst | J.P. Morgan | $12.00 | Buy | +169.7% | Initiated | 07.10.26on TipRanks Oct 14 21:00 | +5.2%next day −0.6% · 5 days −1.5% | ↗ |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $5.00 → $4.50−10.0% | Hold | +1.1% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $5.00 → $4.50−10.0% | Hold | +1.1% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $5.00 → $4.50−10.0% | Hold | +1.1% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $16.00 | Buy | +259.6% | Reiterated | 26.08.26on TipRanks 07:35 | +0.2%next day −2.8% · 5 days −2.6% | ↗ |
| Vamil Divan★★★★★★★★★★#458 · hits 59% · avg +13.5% | Guggenheim | $11.00 | Buy | +147.2% | Reiterated | 20.08.26on TipRanks Aug 21 06:50 | −0.8%next day +1.4% · 5 days −1.1% | ↗ |
| Francois Brisebois★★★★★★★★★★#2595 · hits 43% · avg +5.9% | LifeSci Capital | $10.00 | Buy | +124.7% | Reiterated | 12.08.26on TipRanks 07:50 | +2.1%next day −8.2% · 5 days −1.7% | ↗ |
| Andrew Fein★★★★★★★★★★#267 · hits 52% · avg +23.7% | H.C. Wainwright | $10.00 | Buy | +124.7% | Reiterated | 12.08.26on TipRanks 06:35 | +2.1%next day −8.2% · 5 days −1.7% | ↗ |
| Benjamin Burnett★★★★★★★★★★#5339 · hits 45% · avg +1.7% | Wells Fargo | $9.00 | Buy | +102.2% | Assigned | 11.08.26on TipRanks Aug 12 06:55 | −2.5%next day +2.1% · 5 days −3.2% | ↗ |
| Andreas Argyrides★★★★★★★★★★#1658 · hits 46% · avg +10.2% | Chardan Capital | $11.00 | Buy | +147.2% | Reiterated | 03.06.26on TipRanks 08:10 | +0.7%next day +0.6% · 5 days +0.8% | ↗ |
| Jonathan Wolleben★★★★★★★★★★#249 · hits 53% · avg +23.6% | Citizens JMP | $8.00 → $11.00+37.5% | Buy | +147.2% | Reiterated | 23.10.25on TipRanks 04:55 | −0.4%next day +5.0% · 5 days +3.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Savara
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $11.20 at a price of $5.16 (+117.1%); now: $11.33 at $4.45 (+154.7%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 25 | 20 | 15 | 11 | 7 | 7 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.16 (from $-0.23 to $-0.14). Last quarter: $-0.16.
Best top-analyst consensus in the sector · Healthcare
About Savara
- CEO: Matthew Pauls
- Employees: 70
- The Tannery, Yardley, PA, 19067, US
- www.savarapharma.com
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Data from the stock’s TipRanks forecast page, read 93 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗